Compare Incyte Corporation (INCY) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs PubMatic Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while PubMatic Inc trades at $18.64 (market cap $850.88M). The key difference: Incyte Corporation is far larger — about 26.9× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and PubMatic Inc for 40 Days on average.
| INCY | PUBM | |
|---|---|---|
Market Cap | $22.85B | $850.88M |
Volume | 1,927,029 | 997,698 |
Sector | Health | Technology |
52-Week High | $129.93 | $19.18 |
52-Week Low | $83.80 | $6.28 |
Typical Hold Time | 33 Days | 40 Days |
Enterprise Value | $18.35B | $754.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
PubMatic (PUBM) trades at $18.68, up 0.59% with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results with revenue growth of 11% year-over-year and an EPS beat, though profitability remains challenged with negative net margins. Recent leadership appointments and AI product developments signal strategic focus on growth. Analyst consensus is bullish with 11 buy ratings and a $19.89 price target, representing 6.5% upside potential.
The stock presents a growth opportunity in digital advertising technology with AI-driven products gaining traction, but faces execution risks amid negative profitability and competitive pressures. Revenue growth acceleration and margin improvement will be critical for sustained upside, while current valuation multiples remain elevated relative to earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
